These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 3169375)

  • 1. Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin.
    Corazza GR; Ventrucci M; Strocchi A; Sorge M; Pranzo L; Pezzilli R; Gasbarrini G
    J Int Med Res; 1988; 16(4):312-6. PubMed ID: 3169375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth.
    Di Stefano M; Malservisi S; Veneto G; Ferrieri A; Corazza GR
    Aliment Pharmacol Ther; 2000 May; 14(5):551-6. PubMed ID: 10792117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifaximin, a rifamycin derivative for use in the treatment of intestinal bacterial infections in seriously disabled patients.
    Alvisi V; D'Ambrosi A; Loponte A; Pazzi P; Greco A; Zangirolami A; Palazzini E
    J Int Med Res; 1987; 15(1):49-56. PubMed ID: 3817281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin.
    Peralta S; Cottone C; Doveri T; Almasio PL; Craxi A
    World J Gastroenterol; 2009 Jun; 15(21):2628-31. PubMed ID: 19496193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole.
    Lauritano EC; Gabrielli M; Scarpellini E; Ojetti V; Roccarina D; Villita A; Fiore E; Flore R; Santoliquido A; Tondi P; Gasbarrini G; Ghirlanda G; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2009; 13(2):111-6. PubMed ID: 19499846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome.
    Scarpellini E; Giorgio V; Gabrielli M; Filoni S; Vitale G; Tortora A; Ojetti V; Gigante G; Fundarò C; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1314-20. PubMed ID: 23740443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients.
    Zhao J; Zheng X; Chu H; Zhao J; Cong Y; Fried M; Fox M; Dai N
    Neurogastroenterol Motil; 2014 Jun; 26(6):794-802. PubMed ID: 24641100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin.
    Di Stefano M; Corazza GR
    Chemotherapy; 2005; 51 Suppl 1():103-9. PubMed ID: 15855754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal bacterial overgrowth during chronic pancreatitis.
    Trespi E; Ferrieri A
    Curr Med Res Opin; 1999; 15(1):47-52. PubMed ID: 10216811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-absorbable antibiotics and small bowel bacterial overgrowth.
    Corazza GR; Sorge M; Strocchi A; Benati G; Di Sario A; Treggiari EA; Brusco G; Gasbarrini G
    Ital J Gastroenterol; 1992; 24(9 Suppl 2):4-9. PubMed ID: 1486197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth.
    Majewski M; Reddymasu SC; Sostarich S; Foran P; McCallum RW
    Am J Med Sci; 2007 May; 333(5):266-70. PubMed ID: 17505166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical evaluation of diagnosing bacterial overgrowth in the proximal small intestine.
    Kerckhoffs AP; Visser MR; Samsom M; van der Rest ME; de Vogel J; Harmsen W; Akkermans LM
    J Clin Gastroenterol; 2008; 42(10):1095-102. PubMed ID: 18936644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics.
    Cuoco L; Montalto M; Jorizzo RA; Santarelli L; Arancio F; Cammarota G; Gasbarrini G
    Hepatogastroenterology; 2002; 49(48):1582-6. PubMed ID: 12397741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth.
    Lauritano EC; Gabrielli M; Lupascu A; Santoliquido A; Nucera G; Scarpellini E; Vincenti F; Cammarota G; Flore R; Pola P; Gasbarrini G; Gasbarrini A
    Aliment Pharmacol Ther; 2005 Jul; 22(1):31-5. PubMed ID: 15963077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of trimethoprim-sulfamethoxazole and metronidazole in the treatment of small intestinal bacterial overgrowth in children living in a slum.
    Tahan S; Melli LC; Mello CS; Rodrigues MS; Bezerra Filho H; de Morais MB
    J Pediatr Gastroenterol Nutr; 2013 Sep; 57(3):316-8. PubMed ID: 23974062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth.
    Scarpellini E; Gabrielli M; Lauritano CE; Lupascu A; Merra G; Cammarota G; Cazzato IA; Gasbarrini G; Gasbarrini A
    Aliment Pharmacol Ther; 2007 Apr; 25(7):781-6. PubMed ID: 17373916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study.
    Moraru IG; Portincasa P; Moraru AG; Diculescu M; Dumitraşcu DL
    Rom J Intern Med; 2013; 51(3-4):143-7. PubMed ID: 24620626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome.
    Boltin D; Perets TT; Shporn E; Aizic S; Levy S; Niv Y; Dickman R
    Ann Clin Microbiol Antimicrob; 2014 Oct; 13():49. PubMed ID: 25319626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth.
    Furnari M; Parodi A; Gemignani L; Giannini EG; Marenco S; Savarino E; Assandri L; Fazio V; Bonfanti D; Inferrera S; Savarino V
    Aliment Pharmacol Ther; 2010 Oct; 32(8):1000-6. PubMed ID: 20937045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics.
    Esposito I; de Leone A; Di Gregorio G; Giaquinto S; de Magistris L; Ferrieri A; Riegler G
    World J Gastroenterol; 2007 Dec; 13(45):6016-21. PubMed ID: 18023092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.